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The role of vitamin D-synthesizing enzyme CYP27B1 in systemic lupus erythematosus
1,2

2

2

3

2,

Man LUO , Jing LIU , Yeshuang YUAN , Yong CHEN , GuohuaYUAN *
Division of Rheumatology, Department of Internal Medicine, Suining Central Hospital, Sichuan, China
2
Division of Institute Rheumatology, Department of Internal Medicine, Faculty of Medicine, Affiliated Hospital of North Sichuan
Medical College, Sichuan, China
3
Division of Rheumatology, Department of Internal Medicine, Jianyang People’s Hospital, Sichuan, China
1

Received: 30.10.2021

Accepted/Published Online: 26.03.2022

Final Version: 10.08.2022

Background/aim: To measure the expression of 1α-hydroxylase (CYP27B1) and serum 25(OH)D concentration in systemic lupus
erythematosus (SLE) and to investigate the role of CYP27B1 in SLE.
Materials and methods: Seventy-seven SLE patients and 35 healthy controls (HCs) were enrolled from September 2017 to January 2020.
The study design is cross-sectional. mRNA expression of CYP27B1 in peripheral blood mononuclear cells (PBMCs) was measured by
reverse-transcription quantitative PCR, the protein level of CYP27B1 was quantified by western blotting, and the serum level of 25(OH)
D was determined by an enzyme-linked immunosorbent assay.
Results: The mRNA expression of CYP27B1 in PBMCs was significantly lower in SLE patients than in HCs (p < 0.001), and the
protein quantification confirmed that CYP27B1 expression was lower in SLE patients than in HCs (p = 0.001). Among SLE patients,
the prevalence of lupus nephritis was higher in a subgroup with lower CYP27B1 mRNA expression than in a subgroup with normal
CYP27B1 mRNA expression (41.07% vs. 14.28%, p = 0.028). The mRNA expression of CYP27B1 negatively correlated with the Systemic
Lupus Erythematosus Disease Activity Index (r = −0.331, p = 0.003). Serum 25(OH)D concentration was lower in SLE patients than in
HCs (37.64 ± 19.89 vs. 50.58 ± 12.74 ng/mL, mean ± SD, p = 0.003).
Conclusion: The expression of CYP27B1 in PBMCs may be related to SLE pathogenesis, disease activity, and nephritis.
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1. Introduction
Systemic lupus erythematosus (SLE) is an autoimmune
disease involving multiple organs. It is characterized
by the emergence of autoantibodies, a reduction in the
number of regulatory T cells (Tregs) or a loss of their
function, and excessive proliferation of B cells [1]. An
environment, genes, viruses, and other factors can affect
the initiation and development of SLE. Vitamin D is one
of the environmental factors. Extrarenal transformation of
25(OH)D to 1,25(OH)2D requires mitochondrial enzyme
1α-hydroxylase (CYP27B1), and a variety of immune cells
including monocytes/ macrophages, dendritic cells, B
lymphocytes, and T lymphocytes express CYP27B1 and can
convert 25(OH)D into 1,25(OH)2D. CYP27B1 expression
and activity in immune cells (in contrast to kidneys) can be
regulated by immune signals. Circulating 25(OH)D forms
a complex with vitamin D-binding protein (DBP) and
reaches target cells, such as immune cells. CYP27B1 in the
target cells hydroxylates 25(OH)D to 1,25(OH)2D [2]. The

latter maintains the balance between Tregs and effector
T cells by increasing the number of Tregs and reducing
that of T helper 1 (Th1) cells and Th17 cells, diminishes
memory B-cell counts and antibody levels, and inhibits the
expression of some inflammatory factors [1]. This paper
addresses the role of the vitamin D-synthesizing enzyme
CYP27B1 in SLE.
2. Materials and methods
2.1. Samples
Seventy-seven outpatients and inpatients with SLE in
the Department of Rheumatology and Immunology of
the Affiliated Hospital of North Sichuan Medical College
were enrolled from September 2017 to January 2020,
including 4 males and 73 females, aged 16 to 70 years
(37.76 ± 12.14 years). The exclusion criteria for the SLE
patients were infection, a tumor, liver or renal dysfunction,
diabetes, hypertension, pregnancy, malnutrition, and nonSLE immune diseases. Inclusion criteria were as follows:
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subjects not taking vitamin D or analogues for more
than 1 month, and (for SLE patients) subjects meeting
the diagnostic classification criteria formulated by the
American College of Rheumatology (ACR) in 1997 [3].
The disease activity was evaluated by means of the Systemic
Lupus Erythematosus Disease Activity Index (SLEDAI).
Sex- and age-matched 35 healthy controls (HCs) during
the same season were selected. The study protocol
complied with ethics guidelines and was approved by
the ethics committee of the Affiliated Hospital of North
Sichuan Medical College. The subjects provided informed
consent and signed an informed consent form.
2.2. Methods
2.2.1. Isolation of peripheral blood mononuclear cells
(PBMCs)
Peripheral venous blood (5 mL) was collected from each
subject into a tube containing ethylenediaminetetraacetic
acid (EDTA). PBMCs were isolated by density gradient
centrifugation (2000 g) with a lymphocyte-separating
solution (Tianjin Hao Yang, Biological Products Technology
Co.,Ltd.), according to the manufacturer’s instructions.
2.2.2. Reverse-transcription quantitative PCR (RT-qPCR)
Total RNA was extracted by means of TRIzol (Ambion,
Austin, TX, USA) according to the manufacturer’s
instructions and was dissolved in RNase-free deionized
water. The purity and concentration of RNA were
determined on an ultraviolet spectrophotometer, and
the RNA was reverse-transcribed into cDNA using the
QuantiTect Reverse Transcription kit (Qiagen, Hilden,
Germany), according to the manufacturer’s instructions.
The following primers were used: CYP27B1, forward 5′CCA TGT GGC AGA AGG GAT AA-3′, reverse 5′-AAA
CCG TAA ACC AGG CTA GG-3′; and β-actin, forward 5′CAT CAC GAT GCC AGT GGT ACG-3′, reverse 5′-AAC
CGC GAG AAG ATG ACC CAG-3′. They were synthesized
by the Bioneer company (Korea). The SYBR Green Realtime Quantitative PCR Kit (Qiagen, Hilden, Germany)
was used, and the total reaction volume (20 µL) comprised
double-distilled H2O (7.1 µL), SYBR Green (10.1 µL), a
forward primer (0.4 µL, 10 µM), a reverse primer (0.4 µL,
10 µM), and cDNA (2 µL). The PCR conditions were as
follows: 95 °C for 2 min, 95 °C for 5 s, and 60 °C for 14 s, for
a total of 40 cycles. The reaction was carried out on a Quant
Studio 12K Flex Real-time PCR instrument (ABI, USA).
All the samples were assayed as three technical replicates.
There was no template control. The expression of CYP27B1
is presented as an RQ value. The larger the RQ value, the
higher is relative expression of CYP27B1.
2.2.3. Western blotting
Total protein was extracted from PBMCs of SLE patients
and HCs, and protein concentration was determined
by the bicinchoninic acid assay. In western blots, the

primary antibody was a rabbit monoclonal anti-CYP27B1
antibody (Abcam, UK), and the secondary antibody
was a horseradish peroxidase-conjugated antirabbit IgG
antibody (Proteintech, USA); a rabbit polyclonal antiGAPDH antibody (BODE Bioengineering Co., Ltd.,
China) was used to set up an internal reference. Protein
expression of CYP27B1 in PBMCs was assessed by western
blotting. The amount of total protein loaded on the gel was
40 µg per lane, and the PAGE Gel Rapid Preparation Kit
(10%) was employed (Shanghai Ya Mei Biotechnology Co.,
Ltd., China) for the electrophoresis. After that, the proteins
were transferred to a membrane. The latter was blocked at
4 °C on a shaking table and then incubated overnight (antiCYP27B1 antibody dilution 1:1000, anti-GAPDH antibody
dilution 1:5000) at room temperature with shaking for 1
h. Next, the membrane was probed with the secondary
antibody (dilution 1:5000). After washing, the membrane
was incubated with an electrochemiluminescence (ECL)
reagent for color development, followed by exposure and
imaging. The ImageJ software was used for densitometry
of the protein bands.
2.3. Determination of serum 25(OH)D concentration by
an enzyme-linked immunosorbent assay
This procedure was performed in the Laboratory
Department of the Affiliated Hospital of North Sichuan
Medical College with reagents from Roche (Germany).
2.4. Statistical methods
Statistical analysis was performed in SPSS version 22.0
(IBM, USA). Continuous variables were compared
between groups of independent samples by Student’s t test
for normally distributed data and by the Mann–Whitney
test for data with a nonnormal distribution. Fisher’s exact
test was carried out at t < 1 or 1 < t < 5. Spearman’s rank
correlation analysis was performed to evaluate pairwise
correlations between variables, and data with p < 0.05
were considered statistically significant. The effects of
various factors on the mRNA expression of CYP27B1 were
analyzed using linear regression.
3. Results
3.1 RT-qPCR results
CYP27B1 is expressed in immune cells and hydroxylates
25(OH)D to 1,25(OH)2D, and the latter plays an
immunological part [2]. The mRNA expression of
CYP27B1 in PBMCs was lower in SLE patients than in
HCs (p < 0.001) as shown in Figure 1.
3.2. Western blot results on CYP27B1
Above, we demonstrated that the mRNA expression
of CYP27B1 was lower in SLE patients than in HCs.
Furthermore, the protein quantification confirmed that the
expression of CYP27B1 in PBMCs was lower in SLE patients
than in HCs (p = 0.001), as shown in Figures 2a and 2b.
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3.3.1. mRNA expression of CYP27B1 and analysis of
clinical and laboratory results
We employed the median of CYP27B1 mRNA expression
in the HC group as a cutoff: subjects with a lower value were
assigned to a CYP27B1 mRNA low-expression subgroup,
and those with a higher or equal value were assigned to
a CYP27B1 mRNA normal-expression subgroup. The
results of this analysis are presented in Table.
3.3.2. mRNA expression of CYP27B1 after stratification
by SLE phase and by steroid dose
Patients with SLEDAI < 4 were assigned to a stable-SLE
cohort, and those with SLEDAI ≥ 4 to an active-SLE cohort.
We also distributed all the SLE patients into a steroidfree subgroup, a low-dose steroid subgroup (prednisone
acetate < 10 mg/day), a medium-dose steroid subgroup
(10 mg ≤ prednisone acetate <30 mg), and a high-dose
steroid subgroup (prednisone acetate ≥ 30 mg).
There was no significant difference in the mRNA
expression of CYP27B1 between the no-steroid and lowdose steroid subgroups (t = 1.997, p = 0.053), between

the no-steroid and medium-dose steroid subgroups (t =
1.94, p = 0.847), and between the low-dose steroid and
medium-dose steroid subgroups (F = 0.723, p = 0.485) in
the stable-disease cohort, and between the medium-dose
steroid and high-dose steroid subgroups (t = 0.825, p =
0.417) in the active-SLE cohort. The mRNA expression of
CYP27B1 was lower in the active-SLE cohort than in the
stable-SLE cohort (p < 0.001).
3.4. Correlation between CYP27B1 mRNA expression
and SLEDAI scores
mRNA expression of CYP27B1 among SLE patients
correlated with the SLEDAI score negatively (r = −0.331,
p = 0.003). The more active the disease, the lower was the
mRNA expression of CYP27B1.
3.5. Serum levels of vitamin D
25(OH)D is the main form of vitamin D in blood serum,
and CYP27B1 can hydroxylate 25(OH)D to its active form:
1,25(OH)2D. The serum level of 25(OH)D was significantly
lower in SLE patients than in HCs (p = 0.003) as shown in
Figure 3.

Table. Clinical and laboratory control results of CYP27B1 mRNA expression in patients with SLE.
Project

Low expression group (n = 56)

Normal expression group (n = 21)

p-value

Female:male
Age (year)
Course of disease (month)
Skin lesions [n(%)]
Alopecia [n(%)]
Blood system damage [n(%)]
Arthritis [n(%)]
Renal damage [n(%)]
25(OH)D(ng/mL)
SLEDAI[M(IQR)]
HCQ[n(%)]
Immunosuppressant [n(%)]

53:3
39.59 ± 12.85
56.88 ± 43.66
5(8.9)
2(3.57)
9(16.1)
4(7.1)
23(41.07)
38.89 ± 15.76
2(4)
48(85.7)
56(100)

20:1
35.68 ± 9.4
45.14 ± 48.89
2 (9.5)
0 (0)
2 (9.5)
1 (4.8)
3 (14.28)
33.73 ± 17.97
0 (1.5)
17 (81)
21 (100)

0.917d
0.233b
0.312b
0.936d
1.00d
0.468d
0.708d
0.028d
0.365b
0.028a
0.610c
NS

Notes: SLEDAI: Systemic lupus erythematosus disease activity score.HCQ:Hydroxychloroquine.a: Mann–Whitney test; b: Student’s t
test; c: χ2 test; d: Fisher’s exact test.
CYP27B1mRNA Levels

1.5

***

1.0

0.5

0.0

HC

SLE

Figure 1. Expression of CYP27B1 mRNA in
patients with HC and SLE (*p < 0.05,**p <
0.01, ***p < 0.001) .
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HC

SLE

CYP27B1

50KD

GAPDH

35KD

CYP27B1/GAPDH

1.5

***

1.0

0.5

0.0

HC

SLE

Serum 25(OH)D level(ng/mL)

Figure 2. a) Western blot patterns of CYP27B1, b)
expression of CYP27B1 in patients with HC and SLE (*p
< 0.05,**p < 0.01,***p < 0.001).

60

**

40

20

0

HC

SLE

Figure 3. Comparison of serum 25(OH)D concentration
between patients with HC and SLE (*p < 0.05,**p < 0.01).

4. Discussion
SLE is an autoimmune disease with multiple-organ damage.
Genetic susceptibility, epidemiological risk factors,
and environmental factors can affect the occurrence
and development of SLE. An insufficient serum level of
vitamin D may be an important factor in the pathogenesis
of autoimmunity. Growing epidemiological evidence
indicates that vitamin D deficiency is associated with
higher incidence of autoimmune diseases. The function
of vitamin D in inflammation and immune responses is
mediated by nuclear vitamin D receptor (VDR) in most
immune cells, including monocytes, macrophages, and
activated T and B lymphocytes. 1,25(OH)2D3 can suppress
NF-κB signal transduction and play an immunological
role by upregulating VDR [4].

In addition to expressing VDR, many immune cells
express 1α-hydroxylase (encoded by the CYP27B1 gene),
which can convert 25(OH)D into 1,25(OH)2D. Immune
cells also express 24-hydroxylase (encoded by the
CYP24A1 gene), which is a key enzyme for inactivation
of a variety of vitamin D forms. These cells can respond
not only to active vitamin D metabolites but also to their
precursors and have the function of vitamin D conversion
[5-7]. 1,25(OH)2D binds to VDR to play an immunological
role and to downregulate various inflammatory factors.
Some reports indicate that CYP27B1 is widely expressed
in cells of many tissues and produces 1,25(OH)2D3
locally, which acts in an autocrine or paracrine manner.
1,25(OH)2D3 strongly enhances the expression of the
CYP24A1 gene via a negative feedback loop. The CYP24A1
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enzyme catalyzes the hydroxylation of 25(OH)D or
1,25(OH)2D at position 24 to start catabolic degradation
of this vitamin and to produce inactive metabolites [8, 9].
Our study shows that mRNA and protein expression of
CYP27B1 in PBMCs is significantly lower in SLE patients
than in HCs. The under expression of this enzyme can lead
to a reduction in the amount of locally synthesized active
vitamin D, thereby weakening immune function. These
phenomena probably have an impact on the initiation and
development of an immunological disease.
We collected and analyzed clinical data and found
that the prevalence of lupus nephritis is higher while SLE
is more active in patients with low mRNA expression of
CYP27B1. The expression of CYP27B1 correlated with the
disease activity of SLE among the patients. We analyzed
the correlation between CYP27B1 mRNA expression and
SLEDAI scores. The results revealed a negative correlation,
suggesting that the more active the disease, the lower is
CYP27B1 expression, which can also serve as one of
disease-activity indicators of SLE. After excluding the
effects of immunosuppression and hydroxychloroquine
sulfate, we determined whether steroid therapy affects
CYP27B1 mRNA expression and revealed no significant
effect. Hou [10] and other researchers [11] have reported
that the expression of CYP27B1 and synthetic vitamin
D levels in the placenta and decidua are lower during
spontaneous abortion, resulting in some placental immune
disorders.
Our work showed that serum 25(OH)D concentration
is significantly lower in SLE patients than in HCs. Some
studies indicate that inadequate regulation of extrarenal
CYP27B1 activity makes the serum concentration of
25(OH)D the main determinant of cell 1,25(OH)2D
concentration. Intracellular concentration of 1,25(OH)2D
is directly linked with biological effects. In some endocrine
processes, target cells use 1,25(OH)2D3 as a free ligand
after its dissociation from a transporter globulin called
DBP. In certain autocrine/paracrine processes, 25(OH)D
binds to DBP, reaches target cells, and is locally converted

to 1,25(OH)2D3 [12]. The latter acts in autocrine/paracrine
mode on immune cells. A quantitative decrease of 25(OH)
D in serum can decrease CYP27B1 activity in immune
cells, reduce the local concentration of 1,25(OH)2D3,
and attenuate the corresponding immune regulatory
mechanism. Dutta C [13] and other researchers [14] have
demonstrated that SLE patients with vitamin D deficiency
are more likely to have high disease activity, and patients
with a high SLEDAI score (>10) also have a greater risk of
vitamin D deficiency.
5. Conclusions
Our study showed that the expression of CYP27B1 in SLE
patients may be associated with disease activity. 25(OH)
D levels in the serum of SLE patients were found to be
low; therefore, 1,25(OH)2D hydroxylation by CYP27B1 in
immune cells may be decreased, and the corresponding
immunological process is probably impaired. The
regulation of vitamin D-related enzymes in immune cells
involves the synthesis of 1,25(OH)2D by the CYP27B1
enzyme and degradation of 1,25(OH)2D by CYP24A1. The
expression of CYP27B1 in PBMCs proved to be lower in
SLE patients than in HCs. This study has a limitation: only
CYP27B1 was investigated; therefore, further research is
needed to test whether the imbalance of the two enzymes
is related to SLE.
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